Lineage Cell Therapeutics wins US patent for AlloSCOPE 5D cell manufacturing platform, expiry June 2043

• Lineage Cell Therapeutics secured U.S. Patent No. 12,692,476 covering its AlloSCOPE manufacturing platform, including AlloSCOPE 5D technology.
• Patent protection is expected to run through June 9, 2043.
• Platform targets scalable production of genetically stable pluripotent stem cells for large-dose, off-the-shelf cell therapies.
• Company positions the 5D approach as combining 2D consistency with 3D bioreactor scale to support commercialization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lineage Cell Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609080800BIZWIRE_USPR_____20260908_BW268862) on September 08, 2026, and is solely responsible for the information contained therein.